MedTrace Logo

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

NCT04301011 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-04-23

No results posted yet for this study

Summary

To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).

Conditions

Interventions

BIOLOGICAL

TBio-6517

Engineered Oncolytic Vaccinia Virus

BIOLOGICAL

Pembrolizumab

Immune checkpoint inhibitor.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Turnstone Biologics, Corp.

    lead INDUSTRY

Principal Investigators

  • Ines Verdon, MD · Turnstone Biologics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-02
Primary Completion
2023-01-23
Completion
2023-01-23
FDA Drug
Yes

Countries

  • United States
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04301011 on ClinicalTrials.gov